Oncology

Patients with multiple sclerosis (MS) may experience a slightly increased risk of developing cancer compared to the general population, according to a new nationwide French study spanning 10 years.

Mailed fecal immunochemical testing (FIT) kits using centralized outreach significantly increases colorectal cancer (CRC) screening rates in underserved communities, according to the results of a new study.

The response to tamoxifen, a cornerstone drug in preventing breast cancer recurrence, may hinge on an unexpected factor: gut bacteria.

Even healthy breast tissue harbors rare populations of mutated epithelial cells, raising important questions about their role in breast cancer development.

A randomized clinical trial has revealed that pharmacological ascorbate (high-dose intravenous vitamin C) improves survival outcomes for patients with metastatic pancreatic cancer, a disease with notoriously low 5-year survival rates.

CAR T-cell therapy, a major advancement in treating hematologic cancers, has struggled to show consistent success in solid tumors.

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

A recent study has spotlighted the regulatory divide between the US Food and Drug Administration’s (FDA) Accelerated Approval (AA) pathway and the European Medicines Agency’s (EMA) Conditional Marketing Authorization (CMA) process, showing stark differences in their cancer drug approvals.